Understanding How Biomarkers Can Improve Asthma Care

Eosinophilic inflammation is a central to in Asthma pathogenesis. Blood eosinophils have been shown to be linked to rate of exacerbations and asthma control.¹

In this webinar, Dr David Jackson explores the role of eosinophils in asthma, and the relationship between blood and sputum is discussed. Type 2 inflammation is highlighted in detail, and Type 2 cytokines are presented including interleukin IL-13 and fractional exhaled nitric oxide (FeNO).

The effects of inhaled corticosteroids on FeNO is also discussed, suggesting that FeNO guided management may lead to better outcomes than symptom-based management.²

References

1. Jackson DJ et al. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Advances in Therapy 2020; 37: 718-29.

2. Powell H et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2013; 378:983-990.

We hope that you found the content valuable. To ensure that we continue to provide topics and content of interest, we would very much value your feedback by completing a short questionnaire.

• Dr David Jackson

  Associate Professor, Consultant & Clinical Director

  Read biography
  Dr David Jackson

  Associate Professor, Consultant & Clinical Director Guy’s Severe Asthma Centre

  Role and Location 

  David Jackson is an Associate Professor and consultant in eosinophilic lung diseases and clinical director of Guy’s Severe Asthma Centre.

  Education 

  He qualified from UCL Medical School and subsequently gained an MSc in Allergy and PhD focusing on the role of respiratory viruses in asthma exacerbations from Imperial College.

  Research Interests

  Dr Jackson has authored approximately 100 peer-reviewed publications in the fields of severe asthma, T2 immunity, EGPA, and the role of the eosinophil in lung disease. He edited the ERS monograph on Eosinophilic Lung Diseases and is the chief investigator on multiple phase 2-4 clinical trials in asthma.

  Memberships

  Dr Jackson is member of the GINA assembly, ISAR steering committee, and member of the BTS asthma specialist advisory board.